Abstract: Results of PCP are well known in lupus nephritis. We present here it's outcome in patients with early stage of WH0 type IV lupus nephritis. The criteria for selection was a serum creatinine inferior to 1.3 mg/ 100 ml and a minimum follow up time of 18 months. 35 patients fulfilled the selection criteria. proteinuria, hematuria, leucocyturia, cast, BUN, creatinine, and blood pressure were measured before PCP and after each one. ...
Long-term outcome of pulse cyclophosphamide (PCP) in Behcet's disease (BD) ocular lesions.
Abstract: Since our first report in 1987 to the 11th EULAR congress of rheumatology several reports had shown the efficacy of PCP in posterior uveitis (PU) and retinal vasculitis (RV) of BD. The aim of this report is to show the safety and the efficacy of PCP even in patients who have been followed for more than 2 years (49 cases) . PCP was given as 1g/m2/body surface, once per month, ...
Weekly low-dose pulsed methotrexate in ocular Behcet (analysis of 41 cases).
Abstract: Cytotoxic drugs as the only remittent agents in posterior uveitis (PU) and/or retinal vasculitis (RV) of Aehcet's disease(BD) is generally accepted today. However which cytotoxic is the least harmful and yet efficient is questionable. The safety of long term use of MTX in rheumatoid arthritis made us to use this drug in ocular Behcet. Our prelimi-nary report to the first APLAR Symposium for Treatment of Rheumatic Diseases in Korea, stowed ...
Pulse cyclophosphamide in SLE nephritis, analysis of 84 cases.
Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results with lesser side effects, than oral cytotoxic drugs. We presenthere, our experience with this method, in 84 patients. All patients had a WHO type IV histological lesion, on light microscopy, Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Long-term outcome of cyclophosphamide I.V. bolus in Behcet's disease ocular lesions.
Abstract: Since our first report in 1987 to the XIth EULAR Congress of Rheumatology several reports had proved the efficacy of pulsed cyclophosphamide (PCP) in severe posterior uveitis (PU) and retinal vasculitis (RV) of Behcet's Disease (BD). The aim of this report is to show the outcome of 45 patients who have been followed for more than 2 years. PCP was administered as lg/m2/body surface, once per month, with 0.5 mg ...
Methotrexate in ocular Behcet, preliminary report.
Abstract: Posterior uveitis and retinal vasculitis are the most serious lesions of ocular Behcet. Pulse cyclophosphamide and cyclosporine A are the most efficient treatment. Oral cytotoxic drugs (cyclophosphamide, chlorambucil , and azathioprine) are less efficient. We present here our first impression on weekly pulsed methotrexate (MTX). MTX was administereted as 7.5 mg weekly in 3 divided doses, every 12 hours Prednisolone was given as 0.5 mg/kg/day. 23 patients with posterior uveitis (PU) ...